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Abstract
Objective The aim of this study was to assess progress in patient counselling practices in Finnish
community pharmacies during a national four-year program (TIPPA) from 2000–2003 promoting
enhanced pharmacist–customer communication about medicines.
Method A pseudo customer method was applied. Four visits with four different scenarios were
conducted in a convenience sample of 60 Finnish community pharmacies of different size and
geographic location. In total there were 240 visits during each time point measured (baseline in 2000
and three annual follow-ups, n¼960). The pseudo customers presented three scenarios related to self-
medication and one related to a prescription medicine with a new prescription (baseline and the
second follow-up) or a repeat prescription of the same medication (the first and the third follow-up).
A structured data form customised to each scenario was used to record the interaction.
Key findings Baseline scores were generally low. In two of the four scenarios (one self-medication
and one prescription) a statistically significant improvement (P<0.05) was found in total scores
between the baseline and the third follow-up. Aggregation of the scores of the three self-medica-
tion scenarios did not show any change in counselling practices between the baseline and the third
follow-up, measured as mean total scores (P¼ 0.439).
Conclusions Some improvements were found in pharmacists’ counselling performance in relation
to customers’ requests for advice about nasal products and also when prescription scenarios were
presented. However, pharmacists’ counselling rates were low in relation to a repeat prescription or
when a request was made to buy a specific medicine. Further attention needs to be paid to the latter
two types of consultation.
Introduction
A review of evidence and practice concluded that better outcomes in drug therapies
could be achieved by informing and empowering patients.1 Patient counselling is
considered a key priority for community pharmacists in modern healthcare settings.
Indeed it is mandated by law and regulations in some countries.2–4 This challenges
pharmacy owners to reconstruct their business strategies accordingly and reconfigure
service provision.5,6
Several strategies have been applied to promote patient-oriented counselling prac-
tices: for example, implementing quality standards and promoting the use of specific
guidelines on patient counselling and training for pharmacists or pharmacy assis-
tants.7–10 The content of basic education has been changed to meet the needs of the
new service role.11 Furthermore, specific patients groups, e.g. diabetic patients and
patients with asthma, have been targeted with enhanced patient counselling and
patient education programmes.12,13 Professional programmes e.g. the practice
enhancement programme (PEP) in the US have been developed to enable pharmacists
to acquire skills, knowledge and attitudes to deliver new customer-oriented services.14
However, there is a lack of studies to provide evidence on whether the interventions
have changed practice and, if practice was changed, whether the achieved changes were
sustained.15 Findings from a recent US study conducted using the pseudo customer
method indicated that the intensity of state regulation did have an impact on pharma-
cists’ oral counselling practices.16
One reason for the lack of evidence is a shortage of
reliable and valid measures to assess the quality of new
services and to assure implementation of new business stra-
tegies.5 Patient counselling practices have often been stu-
died by conducting surveys and measuring patient
satisfaction.17–19 Medication counselling has been included
in patient satisfaction and self-evaluation instruments as
one component among many other service quality compo-
nents.20,21 Non-participant observation methods have been
applied in several studies assessing patient counselling prac-
tices in community pharmacies. One method which can
obtain objective and reliable data on patient counselling
practices is the pseudo customer method. It has been
successfully applied e.g. in the US in assessing the impact
of the Omnibus Budget Reconciliation Act of 1990
‘OBRA‘90’ on performance,22 and in evaluating the provi-
sion of written consumer information on medicines.23
In Finland, patient counselling from community pharma-
cies hasbeenmandatedby lawsince 1983.However, a pseudo
customer study conducted in 1998 by the Association of
Finnish Pharmacies revealed room for improvement in
actual performance (Association of Finnish Pharmacies
1998, unpublished) This finding led to an extensive, four-
year, nationally run development project (TIPPA) involving
all the key stakeholders in the field of pharmacy, including
Ministry of Social Affairs and Health. The aim of the study
reportedherewas to assess any changes inpatient counselling
practices in Finnish community pharmacies during the
4-year period of 2000–2003when theTIPPAprojectwas run.
Methods
Intervention
The abbreviationTIPPA stands for ‘customized information
for the benefit of the patient from the community pharmacy’.
The TIPPA project consisted of various planned and
co-ordinated activities supporting a long-term development
process at the pharmacy level. Themainoperational goalwas
to implement a new patient counselling model based on con-
cordanceand two-waycommunication.24Thiswaspromoted
by encouraging pharmacies to produce and implement long-
term development plans by applying methods of strategic
planning, including self-evaluation of current practices.
Pharmacy staff were provided with intensified training and
several resources to support evidence-based communication
about medicines with their customers.9 The main resources
included an electronic, easy-to-use drug information data-
base on prescription medicines based on summaries of pro-
duct characteristics (SPC) launched in 2000; therapeutic
guidelines on self-medication launched in 2000 and 2001;
a handbook on communication skills launched in 2001; and
a quality manual introducing the principles of processing a
long-term development plan launched in 2002. Their imple-
mentation was supported by national, local and in-house
training. The implementation rate was assessed by a survey
amongpractitioners 10months and2.5 years after the project
was started (a convenience sample at 10 months, n¼ 370,
response rate 82%, and a representative sample at 2.5 years,
n¼ 734, response rate 51% ).25,26
Pseudo customer method
Data were collected using a covert pseudo customer
method, i.e. the person being assessed was not aware of
the simulated patient’s identity or purpose.27 A pseudo
customer visit involves a person unknown to pharmacy
staff entering the pharmacy (a pseudo customer) and
requesting specific product or general advice. The visit
may take place at any time within a given time frame.
The pseudo customer is trained to follow a standard script.
The pseudo customer visits were conducted in a con-
venience sample of 60 community pharmacies from the
total number of about 580 outlets. The characteristics of
the sample pharmacies are summarised in Table 1. The
Table 1 Demographic profile of the study pharmacies (n¼ 60) and target group (n¼ 600)
Variable Study pharmacies Target group
n % n %
Service design
Traditional counter 22 37 256 43
Separate self-care department 38 63 141 24
Combination of both 203 33
Geographic location of the pharmacy (county)
Capital and Southern Finland 15 25 150 25
Southeastern Finland 10 17 58 10
South Ostrobothnia 14 23 59 10
Eastern and Central Finland 13 22 51 9
Pirkanmaa 8 13 68 11
Other parts of Finland 0 0 214 35
Annual prescription volume
<50 000 40 67 321 54
>50 000 20 33 279 46
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pharmacies were from different geographic locations and
had a range of service designs. In pharmacies with self-
care departments, customers have direct access to non-
prescription medicines with the availability of a pharma-
cist to provide advice, while pharmacies with a ‘tradi-
tional’ service design have a counter where customers
can obtain their prescription and non-prescription medi-
cines. In Finland, only qualified pharmacists are allowed
to dispense medicines and counsel customers in pharma-
cies. There are two pharmaceutical qualifications in
Finland, Master of Pharmacy degree (MSc Pharm.) and
Bachelor of Pharmacy degree (BcScPharm.). Pharmacists
with a Bachelor’s degree are mostly responsible for custo-
mer service and patient counselling.
Scenarios
Thepseudocustomervisitswere conductedwith fourdifferent
scenarios in each pharmacy, yielding 240 visits per each time
pointmeasured (baseline inDecember 1999–March2000, and
three follow-ups inDecember 2000–January 2001;November
2001–December 2001; and January 2003–February 2003,
respectively). In total, 960 interactions were analysed, 240
interactions for each scenario.
The scenarios were selected to represent different types
of common requests in pharmacies (Appendix 1). Three
were about self-medication and were based on sales sta-
tistics, representing some of the most typical symptoms
for self-medication.28 The fourth concerned a prescription
medication: a new (the baseline and the second follow-up)
and also a repeat prescription of the same medication (the
first and the third follow-up). Pseudo customers were
instructed not to initiate discussion except in the symp-
tom-based scenario (scenario 2) where the customer asked
for advice. The scenarios were developed by the members
of the TIPPA Executive Committee, representing experts
in the field of pharmacy practice, research, education and
administration to ensure the practicality and validity of
the scenarios. The scenarios were then reviewed by the
Department of Pharmacology, University of Helsinki.
Data collection
The visits were conducted by a research institute specialis-
ing in pseudo customer studies. The research institute
trained the pseudo customers according to instructions
from the TIPPA Executive Committee, and the insti-
tute independently selected the study pharmacies. The
pseudo customers (n¼ 9) worked for the research institute
and were from varying professional backgrounds (e.g.
teachers, economists). Depending on the scenario, there
were some differences in the numbers of pseudo customers
used over the study period. Four different pseudo custo-
mers were employed for scenario 1, two for scenarios 2
and 4 and the same pseudo customer did all the visits for
scenario 3. The pseudo customers worked as a team, and
at the end of each day they reviewed all of that day’s data
collection forms. The pseudo customers piloted the sce-
narios in community pharmacies and pretested the data
forms in practice before the study began. Based on the
pilot test, small changes were made to the data collection
forms.
During the baseline, structured forms were the only
method used to record the interaction. During the three
follow-up studies, a small number of the visits were also
audiotaped to obtain more detailed information about the
content of interaction, and to assure the reliability of the
structured coding. The research company was responsible
for the quality assurance of coding.
Scoring system
A scoring system was developed to analyse the interac-
tions between the pseudo customer and the pharmacist
(Appendix 1). Only pieces of information that were
regarded as essential in each scenario were included in
the scoring. The scoring criteria were based on the
United States Pharmacopeia (USP) Medication
Counselling Behaviour Guidelines that introduces the
principles of two-way communication.24 Total scores
and scores for the two subscales ‘Needs assessment’ and
‘Instructions for use’ were calculated for each visit
(Appendix 1). The ‘Needs assessment’ subscale included
items related to clinical assessment, such as who is the
medicine for and what are the symptoms. The
‘Instructions for use’ subscale included information on
how to use the medicine, such as the dosage and the
duration of the treatment. Both of these subscales were
customised according to each individual scenario. One
point was allocated for each item, yielding a maximum
score between 5 and 8 depending on the scenario.
Data analysis
In addition to calculating total scores and scores for sub-
scales for each visit, descriptive statistics were computed,
including means, standard deviations (SDs) and frequency
distributions by using SPSS 10.1. statistical software. The
total scores and scores for the two subscales for each sce-
nario were calculated and the non-parametric Friedman test
was used to test for any statistical difference in mean scores
between the baseline and the final measurement. The total
scores for the three self-medication scenarios were sum-
marised at each time point measured. As the data were not
normally distributed, the non-parametric Friedman test was
used to test for statistical significance in mean total scores
between the baseline and the final measurement. P values
less than 0.05 were considered to be significant.
Ethical considerations
All the Finnish community pharmacies were sent an infor-
mation leaflet about the pseudo customer study by the
Association of Finnish Pharmacies four weeks before the
baseline assessment. Pharmacies could decline to partici-
pate by informing the Association of Finnish Pharmacies
by telephone, and seven did so. Pharmacies were blinded
for the scenarios, pseudo customers and time of visits. No
reminders were sent during the project.
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Results
The mean scores for each scenario at each of the four time
points are shown numerically in Table 2 and as a histo-
gram in Figure 1. Two of the four scenarios showed a
statistically significant improvement (P<0.05) between
the baseline and the third follow-up measured as mean
total scores (Table 2). In scenario 1 (a product request),
scores for both subscales ‘Needs assessment’ and
‘Instructions for use’ showed a significant improvement
(Figure 1). For scenario 4, only a new prescription was
associated with a significant increase in scores for the
subscale ‘Needs assessment’ (Figure 2), but both a new
prescription and the repeat one showed an increase in the
scores for the subscale ‘Instructions for use’ (Figure 2). In
scenarios 2 (a symptom-based request) and 3 (a direct
product request), the only statistically significant changes
found concerned the ‘Instructions for use’ scale and this
revealed a decline between the baseline and the final mea-
surement (Figure 1).
The amount of information provided to the pseudo
customers showed an increase in the scores obtained per
visit (Table 3) for three of the four scenarios. The excep-
tion was the direct product request (scenario 3) where the
proportion of pseudo customers receiving information
remained almost stable at each time point measured.
Between zero and 10% of the pseudo customer inter-
actions had maximum scores at the baseline, the propor-
tion varying according to scenario. The proportion of
pseudo customers that received no information included
in the scoring criteria decreased in two of the four scenar-
ios during the project (scenarios 1 and 4).
The proportion of pseudo customers receiving at least one
piece of information included in the scoring criteria increased
from 48% (n¼ 29) to 70% (n¼ 42) in scenario 1 between
baseline and final follow-up (P¼ 0.003). In scenarios 2 and
3, the scores showed a declining trend between baseline and
final measurement; from 27% (n¼ 16) to 20% (n¼ 12,
P¼ 0.583) and from 93% (n¼ 56) to 78% (n¼ 47,
P¼ 0.487), respectively. In scenario 4, when the pseudo cus-
tomer presented a new prescription she was given at least one
piece of information in 62% (n¼ 37) of patient–pharmacist
interactionsatbaselineand in77%(n¼ 46,P¼ 0.121)during
the second follow-up. With the repeat prescription, the pro-
portions increased from2%(n¼ 1) during the first follow-up
to 12% (n¼ 7, P¼ 0.028) at the final follow-up. Overall the
results show that a very limited amount of information was
given to pseudo customers presenting a repeat prescription.
Statistical analysis of the aggregated total scores for the
three self-medication scenarios between the baseline and the
third measurement revealed no significant differences,
P¼ 0.439 (the baseline: mean 3.77, SD 2.36; the first fol-
low-up: mean 3.42, SD 2.61; the second follow-up: mean
3.77, SD 2.52; and the third follow-up: mean 3.82,
SD 3.03).
Further data analysis might identify factors affecting
counselling practices e.g. prescription volume, service
design, pharmacist’s qualification. Preliminary results
from the statistical analysis indicated that no single factor
could explain the differences in performance.
Discussion
Our findings indicate that some changes took place in the
medication counselling behaviours of Finnish community
pharmacists during 2000–2003. However, it is difficult to
attribute to what extent the positive changes were due to
the TIPPA project or to the effect of other factors influen-
cing professional service provision. TIPPA has been the
leading professional programme in the pharmacy profes-
sion since its inception in 2000. It has been supported by
all the national stakeholders involved. There is also some
evidence from national surveys that the practitioners were
motivated to carry out the recommended long-term devel-
opment process in their pharmacy. The surveys assessed
the implementation of core actions related to TIPPA 10
months and 2.5 years after the project was started.25,26
Awareness of the project and resources was already 90%
Table 2 Mean total scores and standard deviations according to scenario (n¼ 240 per baseline and each follow-up)
Baseline
mean–SD
1st follow-up
mean–SD
2nd follow-up
mean–SD
3rd follow-up
mean–SD
P (between baseline
and 3rd follow-up
Scenario 1 score
range 0–5
0.83 1.09 0.87 1.03 1.42 1.47 1.53 1.32 0.004*
Scenario 2 score
range 0–6
1.96 1.47 1.95 1.47 1.90 1.46 1.83 1.61 0.081
Scenario 3 score
range 0–8
0.68 1.46 0.60 1.41 0.45 0.85 0.45 1.08 0.327
Scenario 4 (new)
score range 0–7
1.87 1.82 n.a. 2.62 1.81 n.a. 0.006*
Scenario 4 (repeat)
score range 0–7
n.a. 0.02 0.13 n.a. 0.23 0.70 0.023a
aStatistically significant P<0.05.
n.a.¼ not applicable.
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after 10 months, and most pharmacists said they had
taken concrete actions to improve their patient counsel-
ling practices. The second survey found that self-reported
actions typically included routine use of the drug informa-
tion database designed to support oral counselling on
prescription medicines (used daily by 88% of the respon-
dents), improving privacy in customer service facilities
(66%), and enhancing in-house training of the personnel
to develop counselling skills (64%). However, the surveys
were not specially targeted to the 60 study pharmacies
involved in the pseudo customers studies. Thus, we do
not know the actions taken in the 60 study pharmacies.
For this purpose, process indicators would have been
needed as part of the follow-up studies to assess the
impact of the actions taken on performance and to control
potential confounding factors. More research needs to be
focused on this area in the future to understand facilita-
tors of professional services at the pharmacy level.6,9
Although there were some positive changes, there was
not a consistent pattern across the four scenarios, making
it very difficult to draw conclusions about the changes
that may have occurred in medication counselling beha-
viours of Finnish community pharmacists during the four-
year period evaluated. Previous studies using pseudo cus-
tomer methodology have found that variability between
the scenarios may influence the results.29–32 In our study,
the symptom-based request (scenario 2) initiated most
active interaction. On the other hand, a direct product
request with a potential iatrogenic effect of the analgesics
(scenario 3) led to little interaction, although we expected
that the pharmacist would assure safe and proper use
of these medications. In order to reduce the impact of
individual scenarios on the results, a larger number of
scenarios would be needed to reflect the whole range
of drug therapies and pharmacist–customer consultations.
Furthermore, the sample of pharmacies would need to be
representative according to outlets included and scenarios
used, to obtain results that can be generalised.
Anecdotal feedback from the pseudo customers indi-
cated that a lack of manpower in the pharmacies may
have influenced the results, particularly during the final
follow-up. There was a nationally recognised shortage of
pharmacists at that time. However, more systematic data
collection would be needed to confirm this impression.
Another factor potentially influencing the results in 2003
is that generic substitution was due to start in community
Table 3 Scores obtained (zero and at least one piece of
information) according to scenario (% of the visits per scenario per
point of measurement)
Total scores Baseline
%
1st
follow-up %
2nd
follow-up %
3rd
follow-up %
Scenario 1
0 52 48 35 30
1–5 48 52 65 70
Scenario 2
0 7 18 10 22
1–6 93 82 90 78
Scenario 3
0 73 80 73 80
1–8 27 20 27 20
Scenario 4 (new)
0 38 n.a. 23 n.a.
1–7 62 n.a. 77 n.a.
Scenario 4 (repeat)
0 n.a. 98 n.a. 88
1–7 n.a. 2 n.a. 12
n.a.¼not applicable.
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medication (n¼ 60 per scenario per baseline and each follow-up).
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Figure 2 Mean scores for the ‘Needs assessment’ and the ‘Instructions
for use’ subscales for scenario 4 (a new and a repeat prescription).
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pharmacies in April 2003, two to three months after the
final data collection. Other factors that need to be taken
into consideration when interpreting the results are other
long-term professional programmes, quality management
and service development processes that might have been
going on in pharmacies.
Although some improvements took place in patient
counselling practices during the TIPPA project, the results
also revealed deficiencies in performance. First, few cus-
tomers received advice optimally customised to their
symptoms and health problems, i.e. reaching maximum
scores according to scoring criteria. Our results suggest
that further attention should be paid to pharmacists’
interactions with customers making direct product
requests for self-medication and with customers with
repeat prescriptions. It may be the case that pharmacy
practitioners do not have a clear understanding of their
role in supporting patients on long-term therapies and in
taking shared responsibility for reaching therapeutic out-
comes. When customers ask to purchase medicines for
self-medication, pharmacists may assume that the custo-
mer asking for a specific medicine has the knowledge to
use them, and that there is thus no need to ask questions
to assess their therapeutic condition for the treatment.
These issues should be taken into account in the training
of pharmacy students and in continuing education.
Audiotaped transcripts of pharmacists’ consultations
with their customers would give a better understanding
of the detailed content of current counselling and the
therapeutic information discussed. Our experience indi-
cates that it might be valuable to use this method in future
studies. Pseudo customer methodology also needs to be
developed further, e.g. to find out the most reliable way of
quantitatively scoring interactions. Sensitiveness of the
measure (i.e. at what point the measure applied indicates
a change) is crucial for the reliability of the results. In our
study, the scoring criteria were based on USP guidelines
and the same criterion was used for both the new and
repeat prescription. Reliability assessments of the scoring
criteria were not conducted.
Other methods have also been used in assessing patient
counselling practices including, for example, surveys,
observation and diaries. Social survey methodology is
the most widely used approach by pharmacy practice
researchers, accounting for a higher proportion of pub-
lished papers than any other methodology.33 However,
observation seems to be the most reliable survey method
with respect to the accuracy and consistency of counsel-
ling activities compared with self-completion question-
naires and diaries.34
Work is continuing in Finland to further develop commu-
nity pharmacy practice. Stakeholders in Finland have found
nationally co-ordinated, long-termactivities necessary to pro-
mote health policy goals through professional community
pharmacy services. After TIPPA, there will be a permanent,
national co-ordination involving the same key stakeholders,
with a special focus on integrating community pharmacists
into local multidisciplinary co-operation, and on implement-
ing sophisticated pharmacy services needed to assure more
optimum therapeutic outcomes ofmedications.
Conclusions
This study has provided longitudinal data on four types of
patient–pharmacist interaction in Finnish community
pharmacies. Some improvements were found in pharma-
cists’ counselling performance in relation to customers’
requests for advice about nasal products and also when
prescription scenarios were presented. However, pharma-
cists’ counselling rates were low in relation to repeat pre-
scriptions or when a request was made to buy a specific
medicine. Further attention needs to be paid to the latter
two types of consultation.
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Appendix 1: description of the scenarios and scoring criteria
Scenario Scoring criteria CScore
1 Self-medication (a product request) Needs assessment Score range 0–5
A customer enters the pharmacy and asks for a nasal spray.
The medicine is intended for an adult suffering from a
runny nose and a mild flu. The symptoms make it difficult
for the customer to sleep at night. The customer does not
have any allergies and has used nasal sprays occasionally.
Is the medicine for an adult
or a child?
Are the symptoms due to allergy
or flu?
Instructions for use
How to administer the spray into the nose
Harmful effects of long-term use
Consequences of long-term use
1
1
1
1
1
2 Self-medication (a symptom-based request) Needs assessment Score range 0–6
A young (under 25 years) female customer enters the pharmacy.
She asks for medicine for symptoms that are related to vaginal
fungal infection. She has not had any infection before and she
has not used any fungal medications. The symptoms (rash,
leucorrhoea) had started a couple of days ago. She has just
finished taking antibiotics (can’t remember the name of the tablets,
10 days course, 1 tablet per day). She does not take contraceptives
and she has visited a gynaecologist 2 or 3 years ago.
What are the symptoms?
If she had experienced the symptoms
before, were they similar?
Instructions for use
Administration of the pessary
Should be taken as a course
Should be taken at bed time
If the medicine has not had an effect in
four days, must visit a doctor
1
1
1
1
1
1
3 Self-medication (a direct product request) Needs assessment Score range 0–8
A customer (a young man) enters the pharmacy and asks for
analgesics by a brand name (ketoprofen) and a brand of H2
receptor antagonist (ranitidine). The customer has suffered from
headache for a long time, for which he has used ketoprofen,
sometimes also ibuprofen or aspirin. He has had a prescription
for ibuprofen 600mg which was given to him due to workplace
ergonomics. The doctor had also mentioned a possibility of
physical treatments, if the symptoms would not disappear by
adding exercise and changing workplace ergonomics. The customer
has not had time to see a physician since; instead he has bought
analgesics without prescription. He consumes 2–3 tablets almost
daily. He has been taking analgesics for almost six months. Lately
he has been suffering from stomach ache and heartburn (customer
implies it is due to stress and too much coffee). His colleague has
recommended this H2 inhibitor and he has decided to try it. The
customer has not considered seeing a doctor for his stomach ache.
Are both of the medicines for the
customer himself?
Why is he taking these medicines?
How long has he been using analgesics?
How long has he been using ranitidine?
Instructions for use
Customer is told about ranitidine products:
1–2 tablet per day
Should be taken as a one-week course
If symptoms do not disappear, must
visit a doctor
Analgesics may have caused the stomach
ache
1
1
1
1
1
1
1
1
4 Prescription medicine Needs assessment Score range 0–7
A woman (born in 1964) enters the pharmacy with a Ventolin
(salbutamol) inhaler prescription. The customer has had a cough
for a month due to flu. At home, her family complains about her
coughing at night time. She has used some cough medicine that
she had at home but it didn’t seem to help. Her colleagues made
her see a physician and the doctor prescribed a Ventolin inhaler,
which expands the airways and is usually used for the treatment of
asthma. The doctor tells her to take the medicine regularly for a
week and after that only for acute symptoms. She can also use the
cough medicine she has at home, if necessary.
Has she used the medicine before?
What did the doctor tell her about
her medication?
Is the drug intended for the treatment
of asthma?
Instructions for use
Technical instructions for using the inhalator
Information about how the drug works
Possible adverse effects are discussed
Dosage information is given
1
1
1
1
1
1
1
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